| pubmed-article:11821743 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11821743 | lifeskim:mentions | umls-concept:C0014644 | lld:lifeskim |
| pubmed-article:11821743 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:11821743 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:11821743 | lifeskim:mentions | umls-concept:C0024314 | lld:lifeskim |
| pubmed-article:11821743 | lifeskim:mentions | umls-concept:C1510411 | lld:lifeskim |
| pubmed-article:11821743 | lifeskim:mentions | umls-concept:C0596402 | lld:lifeskim |
| pubmed-article:11821743 | lifeskim:mentions | umls-concept:C1512474 | lld:lifeskim |
| pubmed-article:11821743 | lifeskim:mentions | umls-concept:C1553412 | lld:lifeskim |
| pubmed-article:11821743 | lifeskim:mentions | umls-concept:C1548328 | lld:lifeskim |
| pubmed-article:11821743 | lifeskim:mentions | umls-concept:C0664686 | lld:lifeskim |
| pubmed-article:11821743 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:11821743 | pubmed:dateCreated | 2002-1-31 | lld:pubmed |
| pubmed-article:11821743 | pubmed:abstractText | Posttransplant lymphoproliferative disease (PTLD), driven by the presence of Epstein-Barr virus (EBV), is becoming an increasingly important clinical problem after solid organ transplantation. The use of immunosuppressive therapy leads to the inhibition of the cytotoxic T cells that normally control the EBV latently infected B cells. The prognosis for many patients with PTLD is poor, and the optimal treatment strategy is not well defined. | lld:pubmed |
| pubmed-article:11821743 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11821743 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11821743 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11821743 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11821743 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11821743 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11821743 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11821743 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11821743 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11821743 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:11821743 | pubmed:issn | 0041-1337 | lld:pubmed |
| pubmed-article:11821743 | pubmed:author | pubmed-author:MalichGG | lld:pubmed |
| pubmed-article:11821743 | pubmed:author | pubmed-author:SculleyTom... | lld:pubmed |
| pubmed-article:11821743 | pubmed:author | pubmed-author:GabrielliBria... | lld:pubmed |
| pubmed-article:11821743 | pubmed:author | pubmed-author:ParsonsPeter... | lld:pubmed |
| pubmed-article:11821743 | pubmed:author | pubmed-author:KrauerKenia... | lld:pubmed |
| pubmed-article:11821743 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11821743 | pubmed:day | 27 | lld:pubmed |
| pubmed-article:11821743 | pubmed:volume | 73 | lld:pubmed |
| pubmed-article:11821743 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11821743 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11821743 | pubmed:pagination | 271-9 | lld:pubmed |
| pubmed-article:11821743 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:11821743 | pubmed:meshHeading | pubmed-meshheading:11821743... | lld:pubmed |
| pubmed-article:11821743 | pubmed:meshHeading | pubmed-meshheading:11821743... | lld:pubmed |
| pubmed-article:11821743 | pubmed:meshHeading | pubmed-meshheading:11821743... | lld:pubmed |
| pubmed-article:11821743 | pubmed:meshHeading | pubmed-meshheading:11821743... | lld:pubmed |
| pubmed-article:11821743 | pubmed:meshHeading | pubmed-meshheading:11821743... | lld:pubmed |
| pubmed-article:11821743 | pubmed:meshHeading | pubmed-meshheading:11821743... | lld:pubmed |
| pubmed-article:11821743 | pubmed:meshHeading | pubmed-meshheading:11821743... | lld:pubmed |
| pubmed-article:11821743 | pubmed:meshHeading | pubmed-meshheading:11821743... | lld:pubmed |
| pubmed-article:11821743 | pubmed:meshHeading | pubmed-meshheading:11821743... | lld:pubmed |
| pubmed-article:11821743 | pubmed:meshHeading | pubmed-meshheading:11821743... | lld:pubmed |
| pubmed-article:11821743 | pubmed:meshHeading | pubmed-meshheading:11821743... | lld:pubmed |
| pubmed-article:11821743 | pubmed:meshHeading | pubmed-meshheading:11821743... | lld:pubmed |
| pubmed-article:11821743 | pubmed:meshHeading | pubmed-meshheading:11821743... | lld:pubmed |
| pubmed-article:11821743 | pubmed:meshHeading | pubmed-meshheading:11821743... | lld:pubmed |
| pubmed-article:11821743 | pubmed:meshHeading | pubmed-meshheading:11821743... | lld:pubmed |
| pubmed-article:11821743 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:11821743 | pubmed:articleTitle | A histone deacetylase inhibitor, azelaic bishydroxamic acid, shows cytotoxicity on Epstein-Barr virus transformed B-cell lines: a potential therapy for posttransplant lymphoproliferative disease. | lld:pubmed |
| pubmed-article:11821743 | pubmed:affiliation | Queensland Institute of Medical Research and University of Queensland Joint Oncology Program, Herston 4029, Brisbane, Australia. | lld:pubmed |
| pubmed-article:11821743 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11821743 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11821743 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11821743 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11821743 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11821743 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11821743 | lld:pubmed |
